Dyne Therapeutics financials at a glance

+ Portfolio

The revenue of Dyne Therapeutics is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -3.95 Dollars per share in 2023, which was 10.24 lower than 2021. And about -0.18889 billion Dollars are reported as free cash flow in the financials of Dyne Therapeutics 2023. No dividends were paid to the shareholders of the Dyne Therapeutics stock NasdaqGS:DYN in the financial year 2023.

$0.00M

Revenue

$-3.23

Earnings Per Share

0.00%

Gross Margin %

$-,156.71M

Free Cash Flow

Revenue

0.00

Earnings Per Share

-3.23

Gross Margin %

0.00

Free Cash Flow

-,156.71

Financials

Year	Year	TTM	2022	2021	2020
Rev.	Revenue	N/A	$0.00M	$0.00M	$0.00M
GM %	Gross Margin %	0.00%	0.00%	0.00%	0.00%
OM	Operating Margin	0.00%	0.00%	0.00%	0.00%
EPS	Earnings Per Share	$-3.62	$-3.23	$-2.93	$-4.13
Div.	Dividends	N/A	$0.00	$0.00	$0.00
PR %	Payout Ratio %	0	0	0	0
Sha.	Shares	N/AM	56.34M	51.6M	51.46M
OCF	Operating Cash Flow	N/A	$-,153.65M	$-,119.56M	$-46.51M
FCF	Free Cash Flow	N/A	$-,156.71M	$-,123.18M	$-47.67M
FCFS	Free Cash Flow Per Share	$-3.19	$-3.02	$-2.42	$-3.31

Dyne Therapeutics financials at a glance

Financials

Discover